Patterns of Ecstasy-Associated Hyponatremia in California

Annals of Emergency Medicine

Volumn 49, Issue 2, 2007, Pages

  Rosenson, Jonathan ^a,b   Smollin, Craig ^d,e   Sporer, Karl A ^b,e   Blanc, Paul ^b,c,d   Olson, Kent R ^b,c,d  

^a HIGHLAND HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c School of Pharmacy   (United States)

^d California Poison Control System   (United States)

^e SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; ECSTASY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONFIDENCE INTERVAL; DATA BASE; DRUG INTOXICATION; FEMALE; HUMAN; HYPONATREMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; SEX DIFFERENCE; SODIUM BLOOD LEVEL; SYSTEMATIC REVIEW; UNITED STATES; URINALYSIS;

EID: 33846227028     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annemergmed.2006.09.018     Document Type: Article

References (38)

1. Shannon M. Methylenedioxymethamphetamine (MDMA, "ecstasy"). Pediatr Emerg Care 16 (2000) 377-380
2. Patel M.M., Wright D.W., Ratcliff J.J., et al. Shedding new light on the "safe" club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med 11 (2004) 208-210
3. Henry J.A., Jeffreys K.J., and Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ("ecstasy"). Lancet 340 (1992) 384-387
4. Budisavljevic M.N., Stewart L., Sahn S.A., et al. Hyponatremia associated with 3,4-methylenedioxymethamphetamine ("ecstasy") abuse. Am J Med Sci 326 (2003) 89-93
5. Hartung T.K., Schofield E., Short A.I., et al. Hyponatremic states following 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") ingestion. QJM 95 (2002) 431-437
6. White J.M., Bochner F., and Irvine R.J. The agony of "ecstasy". Med J Aust 66 (1997) 117-118
7. Sue Y.M., Lee Y.L., and Huang J.J. Acute hyponatremia, seizure and rhabdomyolysis after ecstasy use. J Toxicol 40 (2002) 931-932
8. Ben-Abraham R., Szold O., Rudick V., et al. Ecstasy intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med 10 (2003) 309-313
9. Schwartz R.H., and Miller N.S. MDMA (ecstasy) and the rave: a review. Pediatrics 100 (1997) 705-708
10. Harris D.S., Baggott M., Mendelson J.H., et al. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 162 (2002) 396-405
11. Kalant H. The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 165 (2001) 917-928
12. Screaton G.R., Singer M., Cairns H.S., et al. Hyperpyrexia and rhabdomyolysis after MDMA ("ecstasy") abuse. Lancet 339 (1992) 677-678
13. Patel M.M., Belson M.G., Longwater A.B., et al. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J Emerg Med 29 (2005) 451-455
14. Singarajah C., and Lavies N.G. An overdose of ecstasy: a role for dantrolene. Anaesthesia 47 (1992) 686-687
15. Burgess C., O'Donohoe A., and Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry 15 (2000) 287-294
16. Kwon C., Zaritsky A., and Dharnidharka V.R. Transient proximal tubular renal injury following ecstasy ingestion. Pediatr Nephrol 18 (2003) 820-822
17. Mueller P.D., and Korey W.S. Death by "ecstasy": the serotonin syndrome?. Ann Emerg Med 32 (1998) 377-380
18. Maxwell D.L., Polkey M.I., and Henry J.A. Hyponatremia and catatonic stupor after taking "ecstasy" [letter]. BMJ 307 (1993) 1399
19. Ajaelo I., Koenig K., and Snoey E. Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med 5 (1998) 839-840
20. Holden R., and Jackson M.A. Near-fatal hyponatraemic coma due to vasopressin over-secretion after ecstasy (3,4-MDMA) [letter]. Lancet 347 (1996) 1052
21. Traub S.J., Hoffman R.S., and Nelson L.S. The "ecstasy" hangover: hyponatremia due to 3 4-methylenedioxymethamphetamine. J Urban Health 4 (2002) 549-555
22. Cherney D.Z., Davids M.R., and Halperin M.L. Acute hyponatremia and "ecstasy": insights from a quantitative and integrative analysis. QJM 95 (2002) 475-483
23. Reneman L., Booij J., de Bruin K., et al. Effects of dose, sex and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358 (2001) 1864-1869
24. Toxic Exposure Surveillance System. Instruction for the Toxic Exposure Surveillance System (TESS) (2001), American Association of Poison Control Centers, Washington, DC
25. Henry J.A., Fallon J.K., and Kicman A.T. Low-dose MDMA ("ecstasy") induces vasopressin secretion [letter]. Lancet 351 (1998) 1784
26. Brownfield M.S., Greathouse J., Lorens S.A., et al. Neuropharmacological characterization of serotoninergic stimulation of vasopressin secretion in conscious rats. Neuroendocrinology 47 (1988) 277-283
27. Forsling M.L., Stromberg P., and Akerlund M. Effect of ovarian steroids on vasopressin secretion. J Endocrinol 95 (1982) 147-151
28. Ayus C.J., Wheeler J.M., and Arieff A.I. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 117 (1992) 891-897
29. Arieff A.I., Kozniewska E., Roberts T.P., et al. Age, gender and vasopressin affect survival and brain adaptation in rats with metabolic encephalopathy. Am J Physiol 268 (1995) R1143-R1152
30. Brvar M., Kozelj G., Osredkar J., et al. Polydipsia as another mechanism of hyponatremia after ecstasy (3,4-methylenedioxymethamphetamine) ingestion. Eur J Emerg Med 11 (2004) 302-304
31. Forsling M.L., Fallon J.K., Shah D., et al. The effect of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharm 135 (2002) 649-656
32. Belton K., and Thomas S.H. Drug-induced syndrome of inappropriate antidiuretic hormone secretion. Postgrad Med J 75 (1999) 509-510
33. McKenna D.J., and Peroutka S.J. Neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). J Neurochem 54 (1990) 14-22
34. Rudnick G., and Wall S.C. The molecular mechanism of "ecstasy" (3,4-methylenedioxymethamphetamine (MDMA)): serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci U S A 89 (1992) 1817-1821
35. Kundi S.A., Forsling M., Kleimestur H., et al. Effect of tamoxifen on pituitary vasopressin level. J Ayub Med Coll Abbottabad 16 (2004) 80-83
36. Stachenfeld N.S., and Keefe D.L. Estrogen effects on osmotic regulation of AVP and fluid balance. Am J Physiol Endocrinol Metab 283 (2002) E711-E721
37. Wang Y.X., Crofton J.T., Liu H., et al. Estradiol attenuates the antidiuretic action of vasopressin in ovariectomized rats. Am J Physiol 268 (1995) R951-R957
38. Available at: http://dancesafe.org/documents/druginfo/ecstasy.php. Accessed January 29, 2005.